leadf
logo-loader
viewErgomed PLC

Ergomed names Stuart Jackson as the group’s chief financial officer with immediate effect

Jackson was recently chief financial officer at Bibby Offshore Holdings Limited where he managed the strategic development and M&A activities and oversaw its recent recapitalisation

New appointment handshake
Ergomed noted also that Jackson was chief financial officer at Acergy SA responsible for the financial restructuring of the business

Ergomed Plc (LSE:ERGO) has announced the appointment of Stuart Jackson as the group’s chief financial officer with immediate effect.

The AIM-listed company, which is focused on providing specialised services to the pharmaceutical industry, said Jackson has “significant international experience in early stage and growth companies as well as managing significant and complex change projects.”

READ: Ergomed revenue delay leads to Numis downgrade

The group noted that he was chief financial officer at Acergy SA responsible for the financial restructuring of the business and implementation of the new business strategy which took Acergy from US$0.1bn to US$6.0bn market capitalisation over a four year period.

More recently it added, he was chief financial officer at CEONA, a Goldman Sachs Capital Partners group of companies, where he was responsible for the early stage set-up and growth of the business, and at Bibby Offshore Holdings Limited where, as chief financial officer, he also managed the strategic development and M&A activities and oversaw its recent recapitalisation.

Stephen Stamp, Ergomed’s chief executive officer of Ergomed commented: "Stuart brings to Ergomed a strong track record of delivery within project and service related businesses on an international scale.

“His experience in non-healthcare services businesses will provide a broader perspective to our project delivery and he will play an integral role in enhancing the strong foundations of Ergomed as we seek to deliver our strategy of taking a market leading position.”

In early morning trading, Ergomed shares were 3.9% higher at 187p.

Quick facts: Ergomed PLC

Price: 800 GBX

AIM:ERGO
Market: AIM
Market Cap: £387.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Expansion of Modus study 'great news for Ergomed Plc'

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics. The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat...

on 11/16/2016

2 min read